세계의 가금류 백신 시장 : 기회, 성장 촉진요인, 산업 동향 분석 및 예측(2024-2032년)

The Global Poultry Vaccines Market was valued at USD 2.3 billion in 2023 and is projected to grow at a CAGR of 7.1% from 2024 to 2032. This growth is driven by increasing global demand for poultry products, such as meat and eggs, fueled by population growth and rising protein consumption. Particularly in emerging economies, the shift towards protein-rich diets has spurred investments in poultry farming, further amplifying the need for effective disease prevention measures, notably animal vaccines.

Projections from the Food and Agriculture Organization (FAO) and the Organization for Economic Co-operation and Development (OECD) underscore the rising demand for poultry products as a key market driver. Their forecasts indicate a 15% growth in global poultry meat consumption over the next decade, estimating a reach of 91 million tons by 2032.

The overall industry is divided into product, disease type, application, dosage form, end-user, and region.

Segmented by product, the market includes attenuated live vaccines, inactivated vaccines, recombinant vaccines, and other types. Dominating the global poultry vaccines market, attenuated live vaccines are projected to grow at 6.9% during the forecast period. Leading the market, attenuated live vaccines are favored for their ability to elicit a robust and enduring immune response. They provide a swift immunity onset, vital for safeguarding young birds and addressing outbreaks promptly. Cost-effective and adaptable, their production and administration often require fewer doses, making them ideal for extensive poultry operations.

Segmented by disease type, the poultry vaccines industry encompasses Newcastle disease, infectious bronchitis, infectious bursal diseases, salmonella, Marek's disease, egg drop syndrome, adenovirus, coccidiosis, avian influenza, infectious laryngotracheitis, avian encephalomyelitis, among others. In 2023, the Newcastle disease segment held the largest market share at 20.8%. Outbreaks lead to substantial economic losses, manifesting as elevated mortality rates, diminished egg production, and stunted growth rates, often resulting in increased culling of affected birds. Such financial repercussions amplify the demand for effective vaccines in the poultry sector.

North America led the global poultry vaccines market and is projected to grow at 7%, aiming for a valuation of USD 1.7 billion by 2032. With its advanced farming practices and technologies, North America's poultry industry, especially in the U.S. and Canada, boasts sophisticated vaccination programs and stringent biosecurity measures, underpinning the regional market growth. As a center for vaccine development innovation, North America's continuous research and advancements in vaccine efficacy and delivery methods will bolster its market growth potential.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising demand for poultry products
    • 3.2.1.2 Increased outbreaks of poultry diseases
    • 3.2.1.3 Technological advancements in vaccine development
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost associated with vaccine development and production
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Attenuated live vaccines
• 5.3 Inactivated vaccines
• 5.4 Recombinant vaccines
• 5.5 Other vaccine types

Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Newcastle disease
• 6.3 Infectious bronchitis
• 6.4 Infectious bursal diseases
• 6.5 Salmonella
• 6.6 Marek's disease
• 6.7 Egg drop syndrome
• 6.8 Adenovirus
• 6.9 Coccidiosis
• 6.10 Avian influenza
• 6.11 Infectious laryngotracheitis
• 6.12 Avian encephalomyelitis
• 6.13 Other disease types

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Breeder
• 7.3 Layer
• 7.4 Broiler

Chapter 8 Market Estimates and Forecast, By Dosage Form, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Liquid vaccine
• 8.3 Freeze dried vaccine

Chapter 9 Market Estimates and Forecast, By End-user, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Veterinary hospitals and clinics
• 9.3 Poultry farms

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
  • 10.3.7 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE
  • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 Biovac
• 11.2 Boehringer Ingelheim International GmbH
• 11.3 Ceva Sante Animale
• 11.4 Dechra Pharmaceuticals PLC
• 11.5 Elanco Animal Health Incorporated
• 11.6 Hester Biosciences Limited
• 11.7 HIPRA
• 11.8 Merck and Co., Inc.
• 11.9 Phibro Animal Health Corporation
• 11.10 Vaxxinova International BV
• 11.11 Venky's Limited
• 11.12 Zoetis, Inc.